Science's Data Search Engine

Key experimentally-testable strategies (visual first; concise second)

1. Conversion therapy + R0 resection after deep systemic response. Rationale: sustained multi‑agent systemic therapy to downstage disease then selective curative-intent surgery—supported by recent consensus and retrospective series in gastric and colorectal cancers; design: prospective randomized trial comparing prolonged induction (~6 months) + R0 resection vs systemic therapy alone with ctDNA-guided selection of surgical candidates. Conversion therapy consensus (gastric)
2. Maximal pathway suppression and combination targeted blockade (example: HER2). Rationale: dual/complete blockade of oncogene-driven signaling can deepen responses and occasionally produce durable remissions—experiment: randomized window-of-opportunity or adaptive trial comparing sequential vs simultaneous dual HER2 blockade plus antibody–drug conjugates in trastuzumab-refractory metastatic HER2+ disease to measure CR and durable remission rates. HER2 progression and combination blockade review
3. Restore tumor antigenicity: upregulate MHC-I / antigen-processing to sensitize tumors to CD8 T cells. Rationale: reversible MHC-I downregulation is common and targetable; experiments: multi-arm phase Ib trials testing STING agonists, epigenetic modulators (DNMTi/HDACi) or STAT3 inhibitors combined with checkpoint inhibitors, with MHC-I expression and ctDNA/multispectral immune profiling as primary PD endpoints and durable CR/cure-fraction estimates as long-term outcomes. MHC-I downregulation review
4. Immunotherapy + local tumor-directed therapies to induce systemic immunity. Rationale: ablative local therapies (radiation, intratumoral agents, electrochemical/alpha therapies) can release neoantigens and promote systemic anti‑tumor immunity when combined with CPIs—experiment: randomized trials of stereotactic ablation + PD-1 blockade vs PD-1 alone, with ctDNA clearance and durable response fraction as outcomes. Local ablation induces systemic immunity (preclinical)
5. Evolutionary double-bind strategies (induce vulnerabilities then target them). Rationale: apply an initial therapy (e.g., RT) that drives predictable adaptation (e.g., upregulation of NK‑ligands), then exploit that adaptation with a second therapy (NK cells, CAR-NK). Proposed experiments: controlled in vivo and patient-derived xenograft studies followed by phase I/II combination trials (RT → NK/CAR-NK) measuring resistant-clone suppression and cure-fraction surrogates (ctDNA-negative durable CR). Evolutionary double-bind (RT→NK)
6. Target tumor‑supporting non-malignant cells in the microenvironment. Rationale: eliminating disease-amplifying stromal/myeloid cells (e.g., uPAR+ pathogenic microglia) can modulate TME to favor tumor control—experiment: analogous strategy for tumors: identify TME-specific surface targets and test local or systemic CAR-T/NK approaches with strict safety windows and PD markers (TME depletion, immune reinvigoration). Example proof-of-concept: uPAR-CAR-T eliminated pathogenic microglia in ALS models. uPAR-CAR-T proof-of-concept (ALS)
7. Block metabolic/immune checkpoints that generate systemic immunosuppression (e.g., IDO1). Rationale: potent IDO1 inhibitors (nanomolar) can reverse tryptophan catabolism–mediated immunosuppression; experiments: combine next‑gen IDO1 inhibitors with CPI in biomarker-selected patients (high kynurenine/IDO1 expression) with ctDNA endpoint and cure-fraction modeling. IDO1 inhibitor chemistry (nanomolar)
8. Optimize systemic therapy sequencing to preserve organ function enabling curative local therapy. Rationale: hepatotoxic chemo (oxaliplatin) can prevent safe liver resection; experiments: prospective studies comparing sequences/doses that maintain resectability (e.g., limiting oxaliplatin cumulative dose, using alternative agents), with histologic liver injury and resection rates as endpoints. Oxaliplatin liver injury affecting surgery

Design principles for experiments to raise cure fraction

• Use strict biomarker-driven selection (ctDNA, PD-L1/HER2/CLDN18.2, MHC-I status) to enrich for patients most likely to achieve complete responses (Conversion therapy consensus (gastric)).
• Use ctDNA as early MRD and clearance biomarker to adapt therapy and define durable molecular remission as surrogate for cure (requires validation across tumor types) (ctDNA MRD challenges (NSCLC)).
• Prioritize combination approaches that mechanistically complement each other (e.g., restore MHC-I + CPI; RT to induce NK ligands → NK therapy) and include PD biomarker windows to prove mechanistic engagement (MHC-I review and combination strategies).
• Embed evolutionary/translational modeling (in silico trials) to predict optimal timing/sequencing and identify designs robust to delayed immunotherapy effects or non-proportional hazards (In silico immunotherapy trial design).

Caveats, blindspots and experimental controls

• Context-dependence: pathways like NF-κB/IFN/STAT3 can have tumor-promoting roles; PD readouts and dose-scheduling experiments are essential (MHC-I pathway dual roles caution).
• Selection bias and publication bias: many high-response retrospective surgical series are from centers of excellence—prospective randomized trials are needed to confirm true cure-rate impact (Need RCTs for conversion therapy).
• Organ toxicity (e.g., oxaliplatin liver injury) can negate curative intent; include histologic and functional organ endpoints in sequencing trials (Oxaliplatin hepatic toxicity).

Operational experimental templates (concise)

• Template A — Conversion RCT (gastric/CRC): enroll biomarker-selected metastatic patients → randomize to (A) standard systemic therapy vs (B) intensified biologic/chemotherapy induction 6 months → assess R0 resection rate, ctDNA clearance at 3/6/12 months, 3‑year cure fraction estimate; adaptive trigger for surgery when ctDNA negative + radiographic CR/major response (Conversion therapy trial template).
• Template B — Mechanism PD trial: small (n=20–40) multi-arm phase Ib evaluating PD engagement (MHC-I upregulation, intratumoral CD8 expansion) of STING agonist vs DNMTi/HDACi ± CPI, with ctDNA and TCR clonality as intermediate endpoints (PD-driven MHC-I restoration trial).
• Template C — Evolutionary double‑bind pilot: sequential RT (fractionation optimized in vitro) → autologous NK or CAR‑NK infusion within days; endpoints: resistant-clone dynamics (sequencing), NK-ligand upregulation, ctDNA reduction, and toxicity (phase Ia safety then expansion) (RT→NK double-bind pilot).

If you want, I can convert these templates into full protocols (eligibility, sample-size calculations, PD assays, statistical plan) or run in-silico trial simulations to optimize designs.

Selected core citations used above (detailed extracts)

• Conversion therapy consensus (gastric)
• MHC-I downregulation review
• HER2 progression/combination review
• Oxaliplatin hepatic toxicity affecting surgery
• RT→NK evolutionary double-bind
• uPAR CAR-T microglia ablation (preclinical)
• IDO1 inhibitor chemistry (preclinical)

Notes on reproducibility & bias: sources include narrative reviews, preclinical studies, early-phase trials, and consensus statements—expect publication bias and center-of-excellence selection effects. Randomized, biomarker‑stratified trials with prespecified PD/ctDNA endpoints are required to convert these experimental strategies into validated increases in cure fraction. Confidence in each strategy is heterogeneous (see scatter), and true validation requires prospective RCTs with long follow-up.